Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular …
W Hiddemann, E Hoster, C Buske, M Dreyling… - 2006 - ashpublications.org
Recent reports have shown a significant improvement of overall survival (OS) in patients
with advanced stage follicular lymphoma (FL) over the last few decades. In order to identify …
with advanced stage follicular lymphoma (FL) over the last few decades. In order to identify …
Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patients
S Sacchi, S Pozzi, L Marcheselli, A Bari… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND. It is unclear whether new treatment modalities have improved the survival
of follicular lymphoma patients. Some data show that there has been no improvement in …
of follicular lymphoma patients. Some data show that there has been no improvement in …
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome …
W Hiddemann, M Kneba, M Dreyling, N Schmitz… - Blood, 2005 - ashpublications.org
Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …
[HTML][HTML] Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the …
C Buske, E Hoster, M Dreyling, R Forstpointner… - Blood, 2008 - Elsevier
We have previously reported that compared to CHOP alone the addition of Rituximab (R) to
CHOP significantly increases the response rate (RR), the time to treatment failure (TTF) and …
CHOP significantly increases the response rate (RR), the time to treatment failure (TTF) and …
[引用][C] Progression‐free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era
A Rivas‐Delgado, L Magnano… - Hematological …, 2017 - Wiley Online Library
Methods: From 570 patients consecutive diagnosed with FL in 2 institutions between 2001
and 2014, we selected 349 patients (median age, 58 years; F/M 188/161; grade 1 74/297 …
and 2014, we selected 349 patients (median age, 58 years; F/M 188/161; grade 1 74/297 …
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival—a study from the groupe d' …
E Bachy, P Brice, R Delarue, N Brousse… - Journal of clinical …, 2010 - ascopubs.org
Purpose First-line treatment for patients with newly diagnosed follicular lymphoma (FL) still
remains debated, even in the rituximab-based combination therapy era. Few studies have …
remains debated, even in the rituximab-based combination therapy era. Few studies have …
Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial
AA Moccia, C Taverna, S Schär, A Vanazzi… - Blood …, 2020 - ashpublications.org
Abstract The Swiss Group for Clinical Cancer Research (SAKK) conducted the SAKK 35/03
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
randomized trial (NCT00227695) to investigate different rituximab monotherapy schedules …
Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern …
E1496 is a phase III trial designed to evaluate the ability of 2 years (yr) of maintenance
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
rituximab (MR) to prolong progression-free survival (PFS) after CVP (cyclophosphamide 1 …
Rituximab Added αIFN+ CHVP Improves the Outcome of Follicular Lymphoma Patients with a High Tumor Burden: to First Analysis of the GELA-GOELAMS FL-2000 …
GA Salles, C Foussard, M Nicolas, M Franck, D Chantal… - 2004 - ashpublications.org
The monoclonal anti-CD20 antibody rituximab has been shown to induce a high response
rate in follicular lymphoma patients and to improve the outcome when associated with CVP …
rate in follicular lymphoma patients and to improve the outcome when associated with CVP …
[HTML][HTML] Impact of Autologous Stem Cell Transplantation and/or Rituximab on Outcome of Patients with Relapsed Follicular Lymphoma-Retrospective Analysis of 2 …
O Weigert, A Uysal, B Metzner, M Pfreundschuh… - Blood, 2008 - Elsevier
Background: There is no standard therapeutic approach for patients (pts) with relapsed
advanced stage follicular lymphoma (FL). The impact of high-dose therapy followed by …
advanced stage follicular lymphoma (FL). The impact of high-dose therapy followed by …